RBCK1 is an endogenous inhibitor for triple negative breast cancer via hippo/YAP axis

BACKGROUND: Triple negative breast cancer (TNBC) is one of the most lethal breast cancer subtypes. Due to a lack of effective therapeutic targets, chemotherapy is still the main medical treatment for TNBC patients. Thus, it is important and necessary to find new therapeutic targets for TNBC. Recent...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Zhongbo, Su, Peng, Ding, Yinlu, Gao, Honglei, Yang, Huijie, Li, Xin, Yang, Xiao, Xia, Yan, Zhang, Chenmiao, Fu, Mingxi, Wang, Dehai, Zhang, Ye, Zhuo, Shu, Zhu, Jian, Zhuang, Ting
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9590148/
https://www.ncbi.nlm.nih.gov/pubmed/36280829
http://dx.doi.org/10.1186/s12964-022-00963-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9590148/
https://www.ncbi.nlm.nih.gov/pubmed/36280829
http://dx.doi.org/10.1186/s12964-022-00963-8

Ejemplares similares